{"id":7120,"date":"2012-04-22T11:55:03","date_gmt":"2012-04-22T11:55:03","guid":{"rendered":"http:\/\/cardiophile.org\/?p=7120"},"modified":"2012-04-22T11:55:03","modified_gmt":"2012-04-22T11:55:03","slug":"omecamtiv-mecarbil-cardiac-myosin-activator","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/omecamtiv-mecarbil-cardiac-myosin-activator\/","title":{"rendered":"Omecamtiv mecarbil \u2013 cardiac myosin activator"},"content":{"rendered":"

Omecamtiv mecarbil \u2013 cardiac myosin activator<\/span><\/h2>\n

Omecamtiv mecarbil is a cardiac myosin activator being evaluated in the treatment of heart failure. Two studies published in Lancet have evaluated omecamtiv mecarbil. One was a trial in 34 healthy volunteers [1] while another involved 45 heart failure patients [2]\u00a0already on optimal medical treatment for heart failure. The first in man study concluded that there is a dose dependent augmentation of left ventricular function with\u00a0omecamtiv mecarbil. Improvement in stroke volume was to the tune of 15 ml and ejection fraction of seven percent. The dose limiting toxic effect was myocardial ischemia due to\u00a0excessive prolongation of systolic ejection time<\/strong>.\u00a0The phase 2 trial showed improvement in cardiac function in those with heart failure due to left ventricular dysfunction and the authors suggested that omecamtiv mecarbil could be the first drug in a new class of therapeutic agents for heart failure.<\/p>\n

The GALACTIC-HF (Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure) is an international, multicenter, randomized, double-blind, placebo-controlled, event-driven cardiovascular outcomes trial planning to enroll eight thousand patients [3]. Chronic symptomatic heart failure (New York Heart Association functional class II to IV) with left ventricular ejection fraction of 35% or lower will be enrolled, if they have elevated natriuretic peptides and if currently being in hospital for heart failure or history admission or emergency department visit for heart failure within the past year. Primary efficacy outcome would be time to cardiovascular death or first heart failure event.<\/p>\n

References<\/span><\/strong><\/p>\n

    \n
  1. John R Teerlink, Cyril P Clarke, Khalil G Saikali, Jacqueline H Lee, Michael M Chen, Rafael D Escandon, Lyndsey Elliott, Rachel Bee, Mohammad Reza Habibzadeh, Jonathan H Goldman, Nelson B Schiller, Fady I Malik, Andrew A Wolff. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study<\/a>. Lancet. 2011 Aug 20;378(9792):667-75.<\/li>\n
  2. John G F Cleland, John R Teerlink, Roxy Senior, Evgeny M Nifontov, John J V Mc Murray, Chim C Lang, Vitaly A Tsyrlin, Barry H Greenberg, Jamil Mayet, Darrel P Francis, Tamaz Shaburishvili, Mark Monaghan, Mitchell Saltzberg, Ludwig Neyses, Scott M Wasserman, Jacqueline H Lee, Khalil G Saikali, Cyril P Clarke, Jonathan H Goldman, Andrew A Wolff, Fady I Malik. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial<\/a>. Lancet. 2011 Aug 20;378(9792):676-83.<\/li>\n
  3. John R Teerlink, Rafael Diaz, G Michael Felker, John J V McMurray, Marco Metra, Scott D Solomon, Jason C Legg, Gustavo B\u00fcchele, Claire Varin, Christopher E Kurtz, Fady I Malik, Narimon Honarpour. Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF. JACC Heart Fail. 2020 Apr;8(4):329-340.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Omecamtiv mecarbil is a cardiac myosin activator being evaluated in the treatment of heart failure. <\/p>\n","protected":false},"author":1,"featured_media":35933,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-7120","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"yoast_head":"\nOmecamtiv mecarbil \u2013 cardiac myosin activator<\/title>\n<meta name=\"description\" content=\"Omecamtiv mecarbil is a cardiac myosin activator being evaluated in the treatment of heart failure. GALACTIC-HF trial will study drug in over 8000 patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/omecamtiv-mecarbil-cardiac-myosin-activator\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Omecamtiv mecarbil \u2013 cardiac myosin activator\" \/>\n<meta property=\"og:description\" content=\"Omecamtiv mecarbil is a cardiac myosin activator being evaluated in the treatment of heart failure. GALACTIC-HF trial will study drug in over 8000 patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/omecamtiv-mecarbil-cardiac-myosin-activator\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2012-04-22T11:55:03+00:00\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/omecamtiv-mecarbil-cardiac-myosin-activator\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/omecamtiv-mecarbil-cardiac-myosin-activator\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"Omecamtiv mecarbil \u2013 cardiac myosin activator\",\"datePublished\":\"2012-04-22T11:55:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/omecamtiv-mecarbil-cardiac-myosin-activator\\\/\"},\"wordCount\":443,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/omecamtiv-mecarbil-cardiac-myosin-activator\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"articleSection\":[\"General Cardiology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/omecamtiv-mecarbil-cardiac-myosin-activator\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/omecamtiv-mecarbil-cardiac-myosin-activator\\\/\",\"name\":\"Omecamtiv mecarbil \u2013 cardiac myosin activator\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/omecamtiv-mecarbil-cardiac-myosin-activator\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/omecamtiv-mecarbil-cardiac-myosin-activator\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2012-04-22T11:55:03+00:00\",\"description\":\"Omecamtiv mecarbil is a cardiac myosin activator being evaluated in the treatment of heart failure. GALACTIC-HF trial will study drug in over 8000 patients.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/omecamtiv-mecarbil-cardiac-myosin-activator\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/omecamtiv-mecarbil-cardiac-myosin-activator\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/omecamtiv-mecarbil-cardiac-myosin-activator\\\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/omecamtiv-mecarbil-cardiac-myosin-activator\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Omecamtiv mecarbil \u2013 cardiac myosin activator\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Omecamtiv mecarbil \u2013 cardiac myosin activator","description":"Omecamtiv mecarbil is a cardiac myosin activator being evaluated in the treatment of heart failure. GALACTIC-HF trial will study drug in over 8000 patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/omecamtiv-mecarbil-cardiac-myosin-activator\/","og_locale":"en_US","og_type":"article","og_title":"Omecamtiv mecarbil \u2013 cardiac myosin activator","og_description":"Omecamtiv mecarbil is a cardiac myosin activator being evaluated in the treatment of heart failure. GALACTIC-HF trial will study drug in over 8000 patients.","og_url":"https:\/\/johnsonfrancis.org\/professional\/omecamtiv-mecarbil-cardiac-myosin-activator\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2012-04-22T11:55:03+00:00","author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/omecamtiv-mecarbil-cardiac-myosin-activator\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/omecamtiv-mecarbil-cardiac-myosin-activator\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"Omecamtiv mecarbil \u2013 cardiac myosin activator","datePublished":"2012-04-22T11:55:03+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/omecamtiv-mecarbil-cardiac-myosin-activator\/"},"wordCount":443,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/omecamtiv-mecarbil-cardiac-myosin-activator\/#primaryimage"},"thumbnailUrl":"","articleSection":["General Cardiology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/omecamtiv-mecarbil-cardiac-myosin-activator\/","url":"https:\/\/johnsonfrancis.org\/professional\/omecamtiv-mecarbil-cardiac-myosin-activator\/","name":"Omecamtiv mecarbil \u2013 cardiac myosin activator","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/omecamtiv-mecarbil-cardiac-myosin-activator\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/omecamtiv-mecarbil-cardiac-myosin-activator\/#primaryimage"},"thumbnailUrl":"","datePublished":"2012-04-22T11:55:03+00:00","description":"Omecamtiv mecarbil is a cardiac myosin activator being evaluated in the treatment of heart failure. GALACTIC-HF trial will study drug in over 8000 patients.","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/omecamtiv-mecarbil-cardiac-myosin-activator\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/omecamtiv-mecarbil-cardiac-myosin-activator\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/omecamtiv-mecarbil-cardiac-myosin-activator\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/omecamtiv-mecarbil-cardiac-myosin-activator\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"Omecamtiv mecarbil \u2013 cardiac myosin activator"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/7120","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=7120"}],"version-history":[{"count":0,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/7120\/revisions"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=7120"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=7120"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=7120"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}